Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Ahmad, Mohammad Zaki; Alkahtani, Saad A.; Akhter, Sohail; Ahmad, Farhan Jalees; Ahmad, Javed; Akhtar, Mohammad Shabib; Mohsin, Nehal; Abdel-Wahab, Basel A.

doi:10.3109/1061186x.2015.1055570

Cited by 77 publications

(57 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, drug delivery via colloid carrier systems, including liposomes, nanoemulsions, and nanoparticles [23], has become a pharmacological research focus. Like biomembranes, liposomes are composed of lipid membranes, including phospholipids and cholesterol.…”

Section: Discussionmentioning

confidence: 99%

Liposomal Curcumin Targeting Endometrial Cancer Through the NF-κB Pathway

Gong

Zhou

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Emerging evidence suggests that curcumin possesses chemopreventive properties against various cancers. However, its poor bioavailability limits its clinical application. In this study, we aimed to utilize encapsulation in liposomes (Lipo) as a strategy for the clinical administration of curcumin for endometrial carcinoma (EC). Methods: Curcumin was encapsulated in a liposomal delivery system to prepare a formulation of liposomal curcumin (LC). EC cell lines Ishikawa and HEC-1 were treated with the compound and cell proliferation was measured using MTT assay. Hoechst 33258 staining assay and flow cytometry were used to detect apoptosis of the cells. Wound healing and cell invasion assays were employed to monitor cell motility. Underlying target signaling, such as NF-κB, caspases, and MMPs, were further studied via qRT-PCR and western blot. Thereafter, a zebrafish model was used to assess the toxicity of LC. Finally, a zebrafish transplantation tumor model of EC was grown and treated with LC. Tumors were monitored and harvested to study the expression of NF-κB. Results: The formation of LC was successfully developed with excellent purity and physical properties. In vitro, LC resulted in dose-dependent inhibition of proliferation, induction of apoptosis, and suppression of Ishikawa and HEC-1 cell motility. LC treatment also suppressed the activation and/or expression of NF-κB, caspase-3, and MMP-9. No demonstrable toxicity was found in the zebrafish model and tumors were suppressed after treatment with LC. PCR analysis also showed down-regulated expression of NF-κB. Conclusions: LC was successfully prepared and played biological roles against EC probably through negative regulation of the NF-κB pathway in vitro and in vivo, which demonstrates its potential therapeutic effects in EC.

show abstract

Section: Discussionmentioning

confidence: 99%

Liposomal Curcumin Targeting Endometrial Cancer Through the NF-κB Pathway

Gong

Zhou

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…In gastric cancer cell lines, CUR protects against chemoresistance in human gastric cancer cell lines (SGC7901 cells) by down-regulating NF-kB and subsequent NF-kB-mediated anti-apoptotic genes, such as Bcl-2 and Bcl-xL (Chung et al, 2013). It has been also reported that CUR suppresses the expression of epidermal growth factor receptor (EGFR) and was capable of suppressing cell proliferation and migration through inhibition of STAT3 phosphorylation, which contributes to gastric carcinogenesis (Uehara et al, 2014;Ahmad et al, 2015). In spite of excellent therapeutic potential, low-aqueous solubility and rapid systemic elimination limit its application in medicine.…”

Section: Introductionmentioning

confidence: 99%

“…Curcumin can be used extensively to treat a variety of solid tumors, including stomach, breast and colorectal carcinoma (Cui et al, 2006;Ahmad et al, 2015;Da et al, 2015). In gastric cancer cell lines, CUR protects against chemoresistance in human gastric cancer cell lines (SGC7901 cells) by down-regulating NF-kB and subsequent NF-kB-mediated anti-apoptotic genes, such as Bcl-2 and Bcl-xL (Chung et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Various nanomedicine-based therapeutic novel drug deliveries such as polymeric nanoparticles, solid lipid nanoparticles (SLNs), nanostructured lipid nanoparticles (NLCs) and so on, have been designed to carry lipophilic drugs containing ETP or CUR (Snehalatha et al, 2008;Zhang et al, 2011;Ahmad et al, 2015;Kuo & Lee, 2015). NLCs, a new type of lipid nanoparticles, are mixtures of solid lipids with spatially incompatible liquid lipids, which have advantages of improved drug loading capacity and sustained release properties (Müller et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Jiang

Geng²,

Liu³

et al. 2016

Drug Delivery

View full text Add to dashboard Cite

Context: Gastric carcinoma (GC) is one of the most common cancers and the second most frequent cause of cancer-related deaths. Chemotherapy is an important therapeutic modality for GC. However, chemoresistance limited its success rate. Combination chemotherapy is often applied to prevent drug-induced resistance in cancers.Objective: The aim of this study is to evaluate whether the co-delivery of etoposide (ETP) and curcumin (CUR) with one nanoparticle can result in synergistic effects of both drugs. Methods: ETP-and CUR-loaded nanostructured lipid carriers (ETP-CUR-NLC) were prepared by the solvent injection technique. Their average size, zeta potential and drug loading were evaluated. Human gastric cancer cell lines (SGC7901 cells) were used for the testing of in vitro cytotoxicity studies, and in vivo anti-tumor efficacies of the carriers were evaluated on mice bearing SGC7901 cells xenografts.Results: ETP-CUR-NLC has a particle size of 114 nm, EPT-loading quantity of 83% and CURloading quantity of 82%. ETP-CUR-NLC displayed high cytotoxicity and enhanced antitumor activity in vitro and in vivo. Meanwhile, ETP-CUR-NLC displayed low cytotoxicity in normal tissues in vivo. Discussion and conclusion: The results demonstrate that ETP-CUR-NLC can achieve impressive anti-tumor activity. By combining CUR, an effective NF-kB inhibitor, with ETP, a powerful anticancer drug, in NLC, we could improve the therapeutic efficacy in cancer treatments. Our results showed that such co-loaded delivery systems could serve as a promising therapeutic approach to improve clinical outcomes against various malignancies.

show abstract

“…30 Furthermore, these NPs can be utilized for targeted delivery of drugs to improve bioavailability, to sustain drug in target tissues, and to improve the stability of therapeutic agents. 31,32 Properties of the NPs are largely dependent on the polymer employed. 33 Among these polymeric NPs, chitosan (CS)-based nanocarriers have received much attention as a drug delivery system.…”

Section: Introductionmentioning

confidence: 99%

Self-assembled nanoparticles based on amphiphilic chitosan derivative and arginine for oral curcumin delivery

Raja

Zeenat

Arif

et al. 2016

IJN

View full text Add to dashboard Cite

Curcumin (Cur) is a striking anticancer agent, but its low aqueous solubility, poor absorption, hasty metabolism, and elimination limit its oral bioavailability and consequently hinder its development as a drug. To redress these limitations, amphiphilic chitosan (CS) conjugate with improved mucoadhesion and solubility over a wider pH range was developed by modification with hydrophobic acrylonitrile (AN) and hydrophilic arginine (Arg); the synthesized conjugate (AN–CS–Arg), which was well characterized by Fourier transform infrared and 1 H nuclear magnetic resonance spectroscopy. Results of critical aggregation concentration revealed that the AN–CS–Arg conjugate had low critical aggregation concentration and was prone to form self-assembled nanoparticles (NPs) in aqueous medium. Cur-encapsulated AN–CS–Arg NPs (AN–CS–Arg/Cur NPs) were developed by a simple sonication method and characterized for the physicochemical parameters such as zeta potential, particle size, and drug encapsulation. The results showed that zeta potential of the prepared NPs was 40.1±2.81 mV and the average size was ~218 nm. A considerable improvement in the aqueous solubility of Cur was observed after encapsulation into AN–CS–Arg/Cur NPs. With the increase in Cur concentration, loading efficiency increased but encapsulation efficiency decreased. The in vitro release profile exhibited sustained release pattern from the AN–CS–Arg/Cur NPs in typical biological buffers. The ex vivo mucoadhesion study revealed that AN–CS–Arg/Cur NPs had greater mucoadhesion than the control CS NPs. Compared with free Cur solution, AN–CS–Arg/Cur NPs showed stronger dose-dependent cytotoxicity against HT-29 cells. In addition, it was observed that cell uptake of AN–CS–Arg/Cur NPs was much higher compared with free Cur. Furthermore, the in vivo pharmacokinetic results in rats demonstrated that the AN–CS–Arg/Cur NPs could remarkably improve the oral bioavailability of Cur. Therefore, the developed AN–CS–Arg/Cur NPs might be a promising nano-candidate for oral delivery of Cur.

show abstract

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Cited by 77 publications

References 157 publications

Liposomal Curcumin Targeting Endometrial Cancer Through the NF-κB Pathway

Liposomal Curcumin Targeting Endometrial Cancer Through the NF-κB Pathway

Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Self-assembled nanoparticles based on amphiphilic chitosan derivative and arginine for oral curcumin delivery

Contact Info

Product

Resources

About